Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you recommend hypofractionated PMRT with a positive deep margin?
How would you dose?
Answer from: Radiation Oncologist at Community Practice
I have used hypofractionated RT in this setting with final boost to area of positive margin equivalent to 60 Gy
Comments
Radiation Oncologist at Charlotte Hungerford Hospital
Thank you!
Radiation Oncologist at Bismarck Cancer Center
I agree, with a caveat - if the pathology report d...
1396
1399
Sign in or Register to read more
5215
Related Questions
How are you clinically incorporating the data presented from RT Charm at ASTRO 2024?
What fields would you treat for a postmastectomy patient with a single suspected small IMN node on MRI but no other criteria for PMRT and a negative SNB?
When utilizing hypofractionated radiotherapy in the post mastectomy setting, are the nodal regions dose painted to a different dose or the same dose as the chest wall/reconstructed breast?
Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?
Is there a role for radiation therapy for florid LCIS managed with lumpectomy?
What is your preferred method of surveillance after mastectomy?
Have you seen any increased dermatologic toxicity with whole breast or chest wall radiation if patients have received recent or concurrent pembrolizumab?
What is your approach to a tumor bed boost in early stage breast cancer patients with micrometastasis?
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
Thank you!
I agree, with a caveat - if the pathology report d...